+ Follow restless Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 923297
[Title] => LVH risk may be higher in restless legs patients
[Summary] => Frequent periodic leg movements during sleep were associated with left ventricular hypertrophy in patients with restless legs syndrome in a recent study.
[DatePublished] => 2013-03-24 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 203094
[Title] => Cabergoline settles restless leg syndrome
[Summary] => The ergot derivative cabergoline is effective and well tolerated for those with restless leg syndrome, as reported at the annual meeting of the American Academy of Neurology.
It was reported that on 86 patients with moderate to severe idiopathic restless leg syndrome who were randomized to placebo or to 0.5, 1.0, or 2.0 mg of cabergoline (Dostinex) in the evening in a five-week double blind dose-finding study.
[DatePublished] => 2003-04-20 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
)
)
restless
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 923297
[Title] => LVH risk may be higher in restless legs patients
[Summary] => Frequent periodic leg movements during sleep were associated with left ventricular hypertrophy in patients with restless legs syndrome in a recent study.
[DatePublished] => 2013-03-24 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 203094
[Title] => Cabergoline settles restless leg syndrome
[Summary] => The ergot derivative cabergoline is effective and well tolerated for those with restless leg syndrome, as reported at the annual meeting of the American Academy of Neurology.
It was reported that on 86 patients with moderate to severe idiopathic restless leg syndrome who were randomized to placebo or to 0.5, 1.0, or 2.0 mg of cabergoline (Dostinex) in the evening in a five-week double blind dose-finding study.
[DatePublished] => 2003-04-20 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
)
)
abtest